Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-22T15:08:49.305Z Has data issue: false hasContentIssue false

Physical activity and dietary considerations for prostate cancer patients: future research directions

Published online by Cambridge University Press:  06 January 2023

Andrew J Hamblen
Affiliation:
School of Sport, Exercise and Rehabilitation Sciences, University of Hull, Kingston upon Hull, UK
James W Bray
Affiliation:
School of Sport, Exercise and Rehabilitation Sciences, University of Hull, Kingston upon Hull, UK
Mohan Hingorani
Affiliation:
Department of Clinical Oncology, Queen's Centre of Oncology, Castle Hill Hospital, Hull Teaching Hospitals NHS Trust, Cottingham, UK
John M Saxton*
Affiliation:
School of Sport, Exercise and Rehabilitation Sciences, University of Hull, Kingston upon Hull, UK
*
*Corresponding author: John M Saxton, email [email protected]
Rights & Permissions [Opens in a new window]

Abstract

This review considers current evidence on physical activity and dietary behaviours in the context of prostate cancer prevention and survivorship outcomes. Prostate cancer is the second most common cancer amongst men, with over 1⋅4 million newly diagnosed cases globally each year. Due to earlier detection via screening and advances in treatments, survival rates are amongst the highest of all cancer populations. However, hormone treatments (i.e. androgen deprivation therapy) can lead to undesirable body composition changes, increased fatigue and reduced health-related quality of life, which can impair the overall wellbeing of men living with and beyond prostate cancer. Existing research has only provided limited evidence that physical activity and nutrition can impact a man's risk of prostate cancer but cohort studies suggest they can influence survival outcomes after diagnosis. Additionally, data from observational and intervention studies suggest that habitual physical activity (or structured exercise) and healthy diets can help to ameliorate hormone-related treatment side-effects. Current physical activity guidelines state that prostate cancer patients should complete at least three sessions of moderate-intensity aerobic exercise per week, along with two resistance exercise sessions, but dietary guidelines for prostate cancer patients are less well defined. In conclusion, regular physical activity and nutritional interventions may improve survival outcomes and attenuate some adverse side-effects of hormone treatments in men with prostate cancer. However, further research is required to improve our understanding of the health impacts of physical activity (including structured exercise) and nutrition in relation to prostate cancer prevention and survivorship.

Type
Conference on ‘Food and nutrition: Pathways to a sustainable future’
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press on behalf of The Nutrition Society

Introduction

Globally, prostate cancer is the second most common cancer in men, with approximately 1⋅4 million cases and 375 000 deaths per annum(Reference Sung, Ferlay and Siegel1). This is consistent with UK data reported by Cancer Research UK, which shows that the prostate is the most common cancer site in men(2). Incidence rates have increased over the last 15 years, and are predicted to continue, mainly being linked to an increase in life expectancy and an increase in detection rate via screening(Reference Teoh, Hirai and Ho3). Prostate cancer survival rates have also increased, due to advances in treatment and earlier detection due to screening(Reference Kvåle, Auvinen and Adami4). The age-standardised 1-year survival rate in England is 96⋅6 %, and with a corresponding 10-year survival rate of 77⋅6 %(5). Because of the high incidence of prostate cancer, and side-effects associated with the long-term treatment plans of men living with and beyond locally advanced and metastatic disease, it is important to consider the role of physical activity (including structured exercise) and nutrition in strategies for prostate cancer prevention and survivorship.

Over the last 20 years, a large number of observational and intervention studies have investigated the effects of physical activity, structured exercise and dietary behaviours on prostate cancer risk and survivorship outcomes. The aim of this review was to summarise key physical activity and nutrition research in this context and to identify areas where further research is required.

Physical activity and dietary considerations for prostate cancer risk

The 2018 Physical Activity Guidelines Advisory Committee Scientific Report chapter on cancer(6) was informed by a systematic review, which synthesised current evidence on exercise and risk of the common cancers(Reference McTiernan, Friedenreich and Katzmarzyk7). Although there is evidence that habitual physical activity is associated with a 12–25 % reduced risk of seven cancer types, there is no convincing evidence of an inverse association between a physically active lifestyle and risk of developing prostate cancer. A systematic review and meta-analysis of forty-eight cohort studies and twenty-four case-control studies also reported no clear association between habitual physical activity and prostate cancer risk, with point estimates for individual studies indicating risk reductions and increased risk(Reference Benke, Leitzmann and Behrens8). However, supplementary data from this meta-analysis showed that long-term (>10 years), occupational physical activity significantly reduced total prostate cancer incidence by 17 % and long-term recreational physical activity significantly reduced the risk of advanced prostate cancer by 25 %(Reference Benke, Leitzmann and Behrens8). As these results were based on a relatively low number of studies, more research is needed to consolidate these findings.

Regarding dietary influences on risk, the World Cancer Research Fund and American Institute for Cancer Research Continuous Update Project focuses on associations between exercise, diet and cancer risk. Although their previous report(Reference Wiseman9) suggested that diets high in calcium increased prostate cancer risk, in their most recent update, the Expert Panel concluded there was no strong evidence linking any individual food group to the risk of prostate cancer(10). However, the report did state there was limited, but suggestive evidence that dairy products, diets high in calcium and low plasma alpha-tocopherol or selenium concentrations may increase risk, but with further research on these dietary constituents being required. The report also found a significant link between prostate cancer risk and BMI, which has dietary implications, with each additional 5 kg/m2 BMI increment increasing the risk of advanced prostate cancer by 8 % and prostate cancer mortality by 11 %. The World Cancer Research Fund and American Institute for Cancer Research dietary recommendations(10) are therefore mainly focused on helping individuals maintain a healthy weight, as a result of consuming a diet high in wholegrains, vegetables, fruits and beans, reducing the consumption of sugar-sweetened drinks, and avoiding processed foods high in fat or sugar.

Overall, while current evidence suggests that exercise and dietary habits may not directly lower an individual's risk of prostate cancer, an active lifestyle and healthy eating behaviours increase the likelihood of maintaining a healthy weight and, therefore, could indirectly reduce the risk of advanced prostate cancer, and potentially have important implications for prostate cancer survival.

Physical activity and dietary considerations for prostate cancer survival

Previous research(Reference McTiernan, Friedenreich and Katzmarzyk7,Reference Richman, Kenfield and Stampfer11,Reference Friedenreich, Wang and Neilson12) has suggested there may be a link between physical activity and survival outcomes for prostate cancer patients. A prospective study of 1455 prostate cancer patients found patients who completed brisk walking for >3 h per week had a 57 % lower rate of disease progression than patients who walked at an easy pace for <3 h per week(Reference Richman, Kenfield and Stampfer11). Other research has reported similar findings, with prostate cancer patients in the highest quartile of postdiagnosis physical activity having a 42 % reduced risk of all-cause mortality compared with the lowest quartile(Reference Friedenreich, Wang and Neilson12). Furthermore, a review found a 38 % reduction in risk of prostate cancer mortality for men in the highest physical activity category compared with the lowest(Reference McTiernan, Friedenreich and Katzmarzyk7). One limitation of cohort studies which investigate links between physical activity and survival is the possibility of reverse causation. This is where patients with a higher disease burden who have a lower expected survival time are unable to engage in physical activity due to the more severe symptoms they are experiencing. To reduce the risk of reverse causation, it has been recommended to use disease progression rather than mortality as an outcome measure(Reference Richman, Kenfield and Stampfer11).

The importance of regular physical activity for prostate cancer patients is highlighted in current recommendations for cancer patients published by the American College of Sports Medicine(Reference Campbell, Winters-Stone and Wiskemann13). Their review of previously published evidence concluded that participation in structured exercise was safe for prostate cancer patients, and details the amount and type of exercise that should be completed to improve specific health outcomes. Their overall recommendation is that cancer patients should complete moderate-intensity aerobic activity for ≥30 min at least three times per week, along with at least two resistance exercise sessions per week, using at least two sets of 8–15 repetitions at 60 % of one repetition maximum or above, for at least 8–12 weeks. This recommendation is for all cancer patients, although it recognises that potential adaptions may be required for specific subgroups. For example, patients with bone metastases will require modifications to their exercise programmes to reduce fracture risk. Despite these recommendations, and the link between a physically active lifestyle and survival, a survey of prostate cancer patients found that 47⋅5 % were completing no moderate or vigorous physical activity(Reference Galvão, Newton and Gardiner14). This highlights the need for interventions that promote and provide support for long-term physical activity behaviour change.

Studies investigating the relationship between dietary behaviours and prostate cancer survival have also reported some interesting associations. For example, prostate cancer patients in the highest quintile of vegetable fat consumption had a 29 % lower risk of lethal prostate cancer and a 26 % reduced risk of all-cause mortality, while adherence to a Mediterranean diet after diagnosis reduced overall mortality risk by 22 %(Reference Richman, Kenfield and Chavarro15). Moreover, a review suggested several dietary factors, including coffee, cruciferous vegetables and vegetable fats, may reduce the risk of prostate cancer progression by up to 59 %(Reference Peisch, Van Blarigan and Chan16). However, further research is required to corroborate these findings and determine the optimal diet for improving prostate cancer survival outcomes.

As for primary prevention, a potential mediator of reported associations between habitual physical activity, diet and prostate cancer survival is the effect of exercise and healthy dietary behaviours on body weight. A recent review found that a postdiagnosis weight gain of >5 % body weight was associated with a 65 % increased risk of prostate cancer mortality, and 27 % increased risk of all-cause mortality, when compared with stable weight patients postdiagnosis (<3 % increase)(Reference Troeschel, Hartman and Jacobs17). Therefore, physical activity and dietary behaviours, which help to promote a healthy body weight (i.e. reduce the amount of excess body fat), after diagnosis may be important for improving patient survival outcomes.

Physical activity and dietary considerations for the quality of prostate cancer survivorship

Due to the high survival rates for prostate cancer, it is important to consider long-term health and wellbeing. One of the most common treatments is androgen deprivation therapy (ADT), which is given to 38⋅4 % of non-metastatic prostate cancer patients globally, but with the UK rate at 54⋅6 %(Reference Liede, Hallett and Hope18). The aim of ADT is to inhibit the effect of hormones such as testosterone on prostate cancer cell growth(Reference Ridgway and Aning19). Current guidelines published by the National Institute for Health and Care Excellence recommend that ADT may be used as an individual treatment to control prostate cancer growth, or in combination with other treatments such as radiotherapy with a curative intent(20).

While ADT is an important treatment for controlling prostate cancer progression, it has side-effects which may reduce a patient's lifespan and health-related quality of life (HR-QoL). There is evidence of elevated cardiovascular risk for men receiving ADT, with a review of over 22 000 ADT patients finding a 20 % higher risk of cardiovascular morbidity than prostate cancer patients who did not receive ADT(Reference Saigal, Gore and Krupski21). However, this elevated risk has not been found in all studies(Reference Nguyen, Je and Schutz22) and may depend on the type of ADT received(Reference Perrone, Degli Esposti and Giacomini23) or confounding influences, including lifestyle behaviours. Men receiving ADT also frequently report increased feelings of fatigue unrelated to recent activity levels and hot flashes(Reference Langston, Armes and Levy24,Reference Nguyen, Alibhai and Basaria25) . An elevated risk of sexual dysfunction, diabetes, bone fractures and dementia have also been reported v. men who receive active surveillance, with the risk of sexual dysfunction increasing further when ADT is combined with radiotherapy and surgery(Reference Nguyen, Lairson and Swartz26).

Another important side-effect of ADT is the adverse impact it has on body composition, including an increase in body weight associated with accumulation of body fat, often accompanied by a reduction in lean body mass (i.e. bone mineral density and skeletal muscle mass)(Reference Galvão, Spry and Taaffe27). A loss of lean body mass in older men may increase their risk of falls and fractures, impairing their ability to perform daily activities and resulting in a loss of functional independence(Reference Wong, Wong and Zhang28). Furthermore, older age might augment the effect of ADT on skeletal muscle mass. A longitudinal study showed that men on ADT aged >70 years lost 2⋅8 % of their lean body mass over a 3-year period, compared with a 0⋅9 % loss for men <70 years of age(Reference Smith, Saad and Egerdie29). Importantly, men who were within their first 6 months of ADT at the start of the study also lost significantly more lean body mass than men who had already been on ADT for longer than 6 months (3⋅7 v. 2⋅0 %, respectively). These data suggest that men over 70 years, who are starting ADT could be particularly vulnerable to losing lean body mass. Strategies aimed at preserving lean mass in newly diagnosed men >70 years starting on ADT could therefore be particularly important for preserving functional independence and HR-QoL.

Studies have found that exercise programmes (aerobic, resistance, combined) can attenuate the effects of ADT on body composition in prostate cancer patients when compared with usual care(Reference Cormie, Galvão and Spry30,Reference Wall, Galvao and Fatehee31) . A meta-analysis of 11 randomised control trials found that participating in an exercise training programme increased whole-body lean mass by a mean difference of 0⋅7 kg, reduced whole-body fat mass by 0⋅67 % and improved aerobic fitness compared with usual care(Reference Bigaran, Zopf and Gardner32). Similar results have been reported by other systematic reviews(Reference Cormie and Zopf33,Reference Edmunds, Tuffaha and Scuffham34) along with reductions in fatigue(Reference Edmunds, Tuffaha and Scuffham34,Reference Bourke, Smith and Steed35) , and improvements in HR-QoL(Reference Cormie and Zopf33,Reference Bourke, Smith and Steed35) . Collectively, these data highlight the potential benefits of exercise programmes for prostate cancer patients on ADT, in terms of attenuating the adverse effects of treatment on body composition and improvements in HR-QoL. It is important to note that patients are recommended to complete both aerobic and resistance exercise as these may have separate complementary benefits, as well as a combined effect(Reference Campbell, Winters-Stone and Wiskemann13).

One particularly effective strategy for helping to preserve lean body mass is resistance exercise, which promotes muscle protein synthesis(Reference Yarasheski, Zachwieja and Bier36). However, this effect may be blunted in older men(Reference Fry, Drummond and Glynn37) and this may explain why previous studies investigating lean body mass using dual-energy x-ray absorptiometry, found no significant benefit of resistance exercise on lean body mass(Reference Galvao, Nosaka and Taaffe38,Reference Nilsen, Raastad and Skovlund39) . For this reason, nutritional strategies such as concurrent protein supplementation alongside exercise may provide an additional anabolic stimulus to enhance muscle synthesis in older individuals(Reference Tang and Phillips40). Of relevance to prostate cancer patients, a study which investigated the effect of resistance exercise and daily protein supplementation using milk protein concentrate in healthy older men found that this combination led to a 1⋅6 kg improvement in lean mass compared with resistance training alone(Reference Tieland, Dirks and van der Zwaluw41). Similarly, in prostate cancer patients, an intervention combining resistance and impact exercise with protein supplementation improved total lean body mass by 1⋅0 kg compared with usual care, although only in participants with high adherence to the intervention(Reference Via, Owen and Daly42). A recent review concluded that protein supplementation is likely to be beneficial for men with prostate cancer, but highlighted the need for future studies to investigate the combination of resistance exercise with protein supplementation(Reference Umlauff, Weber and Freitag43). While future research is required, the use of protein supplementation alongside exercise provides an example of how exercise and nutrition may be used concurrently as a strategy for reducing the adverse side-effects of ADT, and subsequently preserving a patient's musculoskeletal health, HR-QoL and independence.

An alternative dietary supplement of interest is n-3 fatty acids. It has been proposed that dietary n-3 fatty acids could help to reduce sarcopenia due to their anti-inflammatory effects and their anabolic effects via the mammalian target of rapamycin pathway(Reference Dupont, Dedeyne and Dalle44). A meta-analysis investigating n-3 fatty acid supplementation in older adults found that it led to skeletal muscle mass gain and improved physical function(Reference Huang, Chiu and Hsu45). However, these results have not yet been replicated in prostate cancer patients, with previous research only focusing on the effect of n-3 fatty acids on disease progression(Reference Zuniga, Chan and Ryan46). Importantly, previous research has concluded that daily n-3 fatty acid supplementation of 1 g EPA and 1⋅84 g DHA was well-tolerated and safe, with all adverse events considered minor(Reference Aronson, Kobayashi and Barnard47). Further research aimed at investigating whether the combination of n-3 fatty acid supplementation and exercise could provide a viable strategy for lean mass preservation in prostate cancer patients on ADT is warranted.

It is important to consider several factors when interpreting current evidence. For example, as previously highlighted, the impact of ADT on lean body mass outcomes is dependent on age and the duration of ADT(Reference Smith, Saad and Egerdie29). It seems that studies aimed at investigating the effect of physical activity and dietary interventions in older men starting on ADT are warranted, as the impact of ADT side-effects could be more pronounced than those reported for younger men, and men of all ages who have been receiving ADT for some time. However, most existing research has not targeted older men, and very few studies have been focused on newly diagnosed patients starting on ADT. Additionally, although supervised exercise interventions have been shown to be effective in terms of wide-ranging health outcomes, there is also a need for effective home-based, remotely supervised interventions, which may reduce the cost of intervention delivery, and allow access to patients who are unable to attend supervised sessions for logistical reasons(Reference Lam, Cheema and Hayden48,Reference Hanson, Alzer and Carver49) . Future research should investigate ways to safely reduce the amount of exercise supervision via the provision of cost-effective support for long-term behaviour change (maintenance).

In contrast to recently published exercise guidelines for prostate cancer patients(Reference Campbell, Winters-Stone and Wiskemann13), there are no equivalent dietary guidelines. In a review of potential evidence for dietary guidelines relevant for prostate cancer patients on ADT, it was found that of the sixteen included papers only four examined the effect of a dietary intervention alone, with the other twelve also including elements of exercise, medication or counselling(Reference Barnes, Ball and Galvao50). This combination of diet with other elements is a common research design, which makes it difficult to isolate the effects of dietary changes. Nevertheless, some small-scale studies have suggested health benefits resulting from specific dietary interventions. For example, a pilot study randomised twenty-three prostate cancer patients to either their usual diet or a Mediterranean diet (low saturated fat, 2 fruit + 5 veg/d, no red meat, 3 weekly fish portions, daily portion of nuts/seeds)(Reference Baguley, Skinner and Jenkins51). Patients on the Mediterranean diet had improved fatigue, quality of life, lean body mass and total body mass compared with the control group. Similarly, a study which recruited fifty-nine patients found that high-dose vitamin D supplementation (50 000 IU per week above the RDA) improved the bioelectrical impedence ‘phase angle’ of prostate cancer patients, which is a non-invasive technique used to assess functionality and frailty, and with lower phase angle values signalling the onset of functional decline(Reference Inglis, Fernandez and van Wijngaarden52). However, due to the small sample sizes, further research is required before recommending these dietary changes to prostate cancer patients. Indeed, this is a major limitation of existing nutritional intervention studies, consistent with systematic review evidence, that the majority of studies are either underpowered, at high or unknown risk of bias or too short in duration(Reference Hackshaw-McGeagh, Perry and Leach53).

Physical activity considerations for metastatic prostate cancer patients

Metastatic prostate cancer (advanced prostate cancer) is where the cancer has spread to other sites around the body. Metastatic prostate cancer is considered incurable, and the aim of treatment is to delay disease progression and maintain/improve the patient's HR-QoL(20). The median survival time for metastatic prostate cancer patients was estimated to be 71 months from diagnosis(Reference James, Sydes and Clarke54).

Exercise guidelines from the American College of Sports Medicine recommend the same quantity of exercise for metastatic prostate cancer patients as non-metastatic patients, although recognising the need to modify exercise based on a patient's condition(Reference Campbell, Winters-Stone and Wiskemann13). For example, the location of bone metastases could restrict which areas of the body can safely be ‘loaded’ during exercise, limiting the exercise modalities (particularly resistance exercises) that can be undertaken. It is therefore important that metastatic prostate cancer patients receive an individualised exercise prescription from a qualified exercise professional, in consultation with the patient's medical health care team(Reference Campbell, Cormie and Weller55).

Traditionally, patients with metastatic prostate cancer were excluded from research involving exercise due to safety concerns. Early studies with small sample sizes showed that exercise could be conducted safely by advanced prostate cancer patients, and had benefits such as a 5 % improvement in 400 m walk time, and a 11 % increase in muscle strength(Reference Cormie, Newton and Spry56Reference Galvao, Taaffe and Spry58). These studies used supervised exercise interventions, but with the range of exercises available for each patient being restricted on the basis of their metastatic profile (including bone metastases). However, despite the benefits of exercise, a survey of advanced prostate cancer patients found that only 29 % were meeting aerobic exercise guidelines(Reference Zopf, Newton and Taaffe59).

An increasing number of studies are now focusing on metastatic prostate cancer patients(Reference Newton, Kenfield and Hart60Reference Brown, Murphy and McDermott62). For example, the INTERVAL-GAP4 study is investigating the effect of a supervised 2-year high-intensity aerobic and resistance exercise intervention on survival outcomes in advanced prostate cancer patients(Reference Newton, Kenfield and Hart60). However, high-intensity exercise may not be practical for a large proportion of metastatic prostate cancer patients, and so research investigating more pragmatic, accessible and adoptable exercise interventions is also required. Similarly, factors such as the timing of intervention onset, and balance of face-to-face and remote supervision given to patients, require further research to elucidate the optimal exercise conditions for advanced prostate cancer patients.

Dietary considerations for metastatic prostate cancer patients

A limited number of studies have investigated the effect of dietary interventions on health outcomes in metastatic prostate cancer patients. A feasibility/internal pilot study involving fifty patients with non-localised prostate cancer (26 % metastatic patients) showed that a lifestyle intervention (exercise and dietary advice) including small-group healthy eating seminars led to significant reductions in total energy intake, saturated fat, total fat and monounsaturated fat intake(Reference Bourke, Doll and Crank63). Although the changes in fat intake were also found in the larger randomised controlled trial (N 100; 20 % metastatic patients)(Reference Bourke, Gilbert and Hooper64), the combination of exercise with a dietary intervention makes it difficult to identify whether other changes such as the improvement in HR-QoL are a result of the dietary intervention or exercise. Future research should examine interventions containing only dietary elements to isolate the health benefits of nutritional strategies for metastatic prostate cancer patients. For example, it has been proposed that the Mediterranean diet may have specific properties which could bring health benefits for this patient group(Reference Maroni, Bendinelli and Fulgenzi65).

Conclusions

Limited evidence suggests that regular physical activity and dietary behaviours can impact prostate cancer risk, though they could indirectly reduce risk by helping men to achieve and maintain a healthy body weight. Current research also suggests that a physically active lifestyle and healthy dietary behaviours can reduce the adverse effects of hormone treatment and improve survival outcomes for prostate cancer patients. However, further studies are needed to inform the development of pragmatic interventions that can successfully enhance long-term adherence to existing guidelines and become part of standard medical care.

Financial Support

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflict of Interest

None.

Authorship

A. J. H. and J. M. S. drafted the manuscript. All authors critically reviewed and approved the final version of the manuscript.

References

Sung, H, Ferlay, J, Siegel, RL et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71, 209249.CrossRefGoogle ScholarPubMed
Cancer Research UK (2021) Cancer incidence for common cancers (2016–18). https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared#heading-Zero (accessed August 2022).Google Scholar
Teoh, JY, Hirai, HW, Ho, JM et al. (2019) Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS ONE 14, e0221775.CrossRefGoogle ScholarPubMed
Kvåle, R, Auvinen, A, Adami, H-O et al. (2007) Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 99, 18811887.CrossRefGoogle ScholarPubMed
U.S Department of Health and Human Services (2018) 2018 Physical Activity Guidelines Advisory Committee Scientific Report. https://health.gov/sites/default/files/2019-09/PAG_Advisory_Committee_Report.pdf (accessed September 2022).Google Scholar
McTiernan, A, Friedenreich, CM, Katzmarzyk, PT et al. (2019) Physical activity in cancer prevention and survival: a systematic review. Med Sci Sports Exerc 51, 12521261.CrossRefGoogle ScholarPubMed
Benke, IN, Leitzmann, M, Behrens, G et al. (2018) Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis. Ann Oncol 29, 11541179.CrossRefGoogle ScholarPubMed
Wiseman, M (2008) The second world cancer research fund/American institute for cancer research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective: nutrition society and BAPEN Medical Symposium on ‘nutrition support in cancer therapy’. Proc Nutr Soc 67, 253256.CrossRefGoogle Scholar
World Cancer Research Fund/American Institute for Cancer Research (2018) Continuous update project expert report. https://www.wcrf.org/diet-activity-and-cancer/cancer-types/prostate-cancer/ (accessed August 2022).Google Scholar
Richman, EL, Kenfield, SA, Stampfer, MJ et al. (2011) Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res 71, 38893895.CrossRefGoogle ScholarPubMed
Friedenreich, CM, Wang, Q, Neilson, HK et al. (2016) Physical activity and survival after prostate cancer. Eur Urol 70, 576585.CrossRefGoogle ScholarPubMed
Campbell, KL, Winters-Stone, K, Wiskemann, J et al. (2019) Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc 51, 23752390.CrossRefGoogle ScholarPubMed
Galvão, DA, Newton, RU, Gardiner, RA et al. (2015) Compliance to exercise-oncology guidelines in prostate cancer survivors and associations with psychological distress, unmet supportive care needs, and quality of life. Psychooncology 24, 12411249.CrossRefGoogle ScholarPubMed
Richman, EL, Kenfield, SA, Chavarro, JE et al. (2013) Fat intake after diagnosis and risk of lethal prostate cancer and all-cause mortality. JAMA Intern Med 173, 13181326.CrossRefGoogle ScholarPubMed
Peisch, SF, Van Blarigan, EL, Chan, JM et al. (2017) Prostate cancer progression and mortality: a review of diet and lifestyle factors. World J Urol 35, 867874.CrossRefGoogle ScholarPubMed
Troeschel, AN, Hartman, TJ, Jacobs, E et al. (2020) Postdiagnosis body mass index, weight change, and mortality from prostate cancer, cardiovascular disease, and all causes among survivors of nonmetastatic prostate cancer. J Clin Oncol 38, 20182037.CrossRefGoogle ScholarPubMed
Liede, A, Hallett, DC, Hope, K et al. (2016) International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. ESMO Open 1, e000040.CrossRefGoogle ScholarPubMed
Ridgway, AJ & Aning, JJ (2021) Role of primary care in the management of prostate cancer. Prescriber 32, 1117.CrossRefGoogle Scholar
National Institute for Health and Care Excellence (2021) Prostate cancer: diagnosis and management. https://www.nice.org.uk/guidance/ng131 (accessed August 2022).Google Scholar
Saigal, CS, Gore, JL, Krupski, TL et al. (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110, 14931500.CrossRefGoogle ScholarPubMed
Nguyen, PL, Je, Y, Schutz, FA et al. (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306, 23592366.CrossRefGoogle ScholarPubMed
Perrone, V, Degli Esposti, L, Giacomini, E et al. (2020) Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther Clin Risk Manag 16, 393401.CrossRefGoogle ScholarPubMed
Langston, B, Armes, J, Levy, A et al. (2013) The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer 21, 17611771.CrossRefGoogle ScholarPubMed
Nguyen, PL, Alibhai, SM, Basaria, S et al. (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67, 825836.CrossRefGoogle Scholar
Nguyen, C, Lairson, DR, Swartz, MD et al. (2018) Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer. Pharmacotherapy 38, 9991009.CrossRefGoogle ScholarPubMed
Galvão, DA, Spry, NA, Taaffe, DR et al. (2008) Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 102, 4447.CrossRefGoogle ScholarPubMed
Wong, R, Wong, H, Zhang, N et al. (2019) The relationship between sarcopenia and fragility fracture – a systematic review. Osteoporos Int 30, 541553.CrossRefGoogle ScholarPubMed
Smith, MR, Saad, F, Egerdie, B et al. (2012) Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol 30, 32713276.CrossRefGoogle ScholarPubMed
Cormie, P, Galvão, DA, Spry, N et al. (2015) Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int 115, 256266.CrossRefGoogle ScholarPubMed
Wall, BA, Galvao, DA, Fatehee, N et al. (2017) Exercise improves VO2max and body composition in ADT-treated prostate cancer patients. Med Sci Sports Exerc 49, 15031510.CrossRefGoogle Scholar
Bigaran, A, Zopf, E, Gardner, J et al. (2021) The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 24, 3548.CrossRefGoogle ScholarPubMed
Cormie, P & Zopf, EM (2020) Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer. Urol Oncol 38, 6270.CrossRefGoogle ScholarPubMed
Edmunds, K, Tuffaha, H, Scuffham, P et al. (2020) The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review. Support Care Cancer 28, 56615671.CrossRefGoogle ScholarPubMed
Bourke, L, Smith, D, Steed, L et al. (2016) Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur Urol 69, 693703.CrossRefGoogle ScholarPubMed
Yarasheski, KE, Zachwieja, JJ & Bier, DM (1993) Acute effects of resistance exercise on muscle protein synthesis rate in young and elderly men and women. Am J Physiol Endocrinol Metab 265, E210E214.CrossRefGoogle Scholar
Fry, CS, Drummond, MJ, Glynn, EL et al. (2011) Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis. Skelet Muscle 1, 111.CrossRefGoogle ScholarPubMed
Galvao, DA, Nosaka, K, Taaffe, DR et al. (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38, 4552.CrossRefGoogle ScholarPubMed
Nilsen, TS, Raastad, T, Skovlund, E et al. (2015) Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy. Acta Oncol 54, 18051813.CrossRefGoogle ScholarPubMed
Tang, JE & Phillips, SM (2009) Maximizing muscle protein anabolism: the role of protein quality. Curr Opin Clin Nutr Metab Care 12, 6671.CrossRefGoogle ScholarPubMed
Tieland, M, Dirks, ML, van der Zwaluw, N et al. (2012) Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc 13, 713719.CrossRefGoogle ScholarPubMed
Via, JD, Owen, PJ, Daly, RM et al. (2021) Musculoskeletal responses to exercise plus nutrition in men with prostate cancer on androgen deprivation: a 12-month RCT. Med Sci Sports Exerc 53, 20542065.Google ScholarPubMed
Umlauff, L, Weber, M, Freitag, N et al. (2022) Dietary interventions to improve body composition in men treated with androgen deprivation therapy for prostate cancer: a solution for the growing problem? Prostate Cancer Prostatic Dis 25, 149158.CrossRefGoogle ScholarPubMed
Dupont, J, Dedeyne, L, Dalle, S et al. (2019) The role of omega-3 in the prevention and treatment of sarcopenia. Aging Clin Exp Res 31, 825836.CrossRefGoogle ScholarPubMed
Huang, Y-H, Chiu, W-C, Hsu, Y-P et al. (2020) Effects of omega-3 fatty acids on muscle mass, muscle strength and muscle performance among the elderly: a meta-analysis. Nutrients 12, 3739.CrossRefGoogle ScholarPubMed
Zuniga, KB, Chan, JM, Ryan, CJ et al. (2020) Diet and lifestyle considerations for patients with prostate cancer. Urol Oncol 38, 105117.CrossRefGoogle ScholarPubMed
Aronson, WJ, Kobayashi, N, Barnard, RJ et al. (2011) Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res 4, 20622071.CrossRefGoogle ScholarPubMed
Lam, T, Cheema, B, Hayden, A et al. (2020) Androgen deprivation in prostate cancer: benefits of home-based resistance training. Sports Med Open 6, 112.Google ScholarPubMed
Hanson, ED, Alzer, M, Carver, J et al. Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis Published online: 19 March 2022. doi: 10.1038/s41391-022-00523-8Google Scholar
Barnes, KA, Ball, LE, Galvao, DA et al. (2019) Nutrition care guidelines for men with prostate cancer undergoing androgen deprivation therapy: do we have enough evidence? Prostate Cancer Prostatic Dis 22, 221234.CrossRefGoogle ScholarPubMed
Baguley, BJ, Skinner, TL, Jenkins, DG et al. (2021) Mediterranean-style dietary pattern improves cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: a pilot randomised control trial. Clin Nutr 40, 245254.CrossRefGoogle ScholarPubMed
Inglis, JE, Fernandez, ID, van Wijngaarden, E et al. (2021) Effects of high-dose vitamin D supplementation on phase angle and physical function in patients with prostate cancer on ADT. Nutr Cancer 73, 18821889.CrossRefGoogle ScholarPubMed
Hackshaw-McGeagh, LE, Perry, RE, Leach, VA et al. (2015) A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality. Cancer Causes Control 26, 15211550.CrossRefGoogle ScholarPubMed
James, ND, Sydes, MR, Clarke, NW et al. (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 11631177.CrossRefGoogle ScholarPubMed
Campbell, KL, Cormie, P, Weller, S et al. (2022) Exercise recommendation for people with bone metastases: expert consensus for health care providers and exercise professionals. JCO Oncol Pract 18, e697e709.CrossRefGoogle ScholarPubMed
Cormie, P, Newton, RU, Spry, N et al. (2013) Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 16, 328335.CrossRefGoogle ScholarPubMed
Cormie, P, Galvão, DA, Spry, N et al. (2014) Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study. Support Care Cancer 22, 15371548.CrossRefGoogle ScholarPubMed
Galvao, DA, Taaffe, DR, Spry, N et al. (2018) Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc 50, 393399.CrossRefGoogle ScholarPubMed
Zopf, EM, Newton, RU, Taaffe, DR et al. Associations between aerobic exercise levels and physical and mental health outcomes in men with bone metastatic prostate cancer: a cross-sectional investigation. Eur J Cancer Care 26, e12575. doi: 10.1111/ecc.12575Google Scholar
Newton, RU, Kenfield, SA, Hart, NH et al. Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open 8, e022899. doi: 10.1136/bmjopen-2018-022899CrossRefGoogle Scholar
Evans, HE, Forbes, CC, Galvão, DA et al. (2021) Evaluating a web-and telephone-based personalised exercise intervention for individuals living with metastatic prostate cancer (ExerciseGuide): protocol for a pilot randomised controlled trial. Pilot Feasibility Stud 7, 116.CrossRefGoogle ScholarPubMed
Brown, M, Murphy, M, McDermott, L et al. (2019) Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT). Pilot Feasibility Stud 5, 111.CrossRefGoogle ScholarPubMed
Bourke, L, Doll, H, Crank, H et al. (2011) Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomarkers Prev 20, 647657.CrossRefGoogle ScholarPubMed
Bourke, L, Gilbert, S, Hooper, R et al. (2014) Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 65, 865872.CrossRefGoogle ScholarPubMed
Maroni, P, Bendinelli, P, Fulgenzi, A et al. (2021) Mediterranean diet food components as possible adjuvant therapies to counteract breast and prostate cancer progression to bone metastasis. Biomolecules 11, 1336.CrossRefGoogle ScholarPubMed